BOULDER, Colo., March 25 /PRNewswire-FirstCall/ -- Encision Inc. ("Encision") (OTC Bulletin Board: ECIA), a medical device company owning patented surgical technology that is emerging as a standard of care in minimally-invasive surgery, has entered into an agreement with Caldera Medical, Inc. ("Caldera") to represent Caldera's line of products. Caldera's products include the Desara(R) Sling System for treating stress urinary incontinence which is estimated to affect 15 million women in the U.S. Encision will use its sales employees to supplement Caldera's sales team in introducing Caldera's products to physicians and hospitals.
"We are pleased to expand our product offerings to a key group of our target customers. Caldera's products are consistent with our desire to offer 'best in class' products to the surgical market," said Jack Serino, President and CEO of Encision.
"Through Encision's experienced sales representatives, we will expand coverage throughout the U.S. market and strengthen our presence in the marketplace. This is especially important as we continue to broaden our product portfolio with innovative new technologies," said Bryon L. Merade, CEO of Caldera.
Encision designs, develops, manufactures and markets innovative surgical devices that allow surgeons to optimize technique and patient safety during a broad range of surgical procedures. Based in Boulder, Colorado, the Company pioneered the development of patented AEM(R) Laparoscopic Instruments to improve electrosurgery and reduce the chance for patient injury in minimally invasive surgery. For more information, visit Encision's web site at www.encision.com.
Caldera is dedicated to bringing innovative medical devices to the marketplace. Caldera focuses exclusively on differentiated, high-impact products across the gynecology, urology and urogynecology specialties. Caldera is a privately held company located in Agoura Hills, California. For more information, visit Caldera's web site at www.calderamedical.com.
In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to increase net sales through the Company's distribution channels, insufficient quantity of new account conversions, insufficient cash to fund operations, scale up production to meet delivery obligations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission.
CONTACT: Marcia McHaffie, Encision Inc., 303-444-2600, email@example.com
|SOURCE Encision Inc.|
Copyright©2009 PR Newswire.
All rights reserved